<DOC>
	<DOC>NCT00221624</DOC>
	<brief_summary>Response to a second-line anti-HCV treatment in non responder patients to a first-line dual therapy remains very poor. Preliminary studies of amantadine suggest that this drug could be potentially effective to treat hepatitis C.</brief_summary>
	<brief_title>Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients</brief_title>
	<detailed_description>Background : Response to a second-line anti-HCV treatment in non responder patients to a first-line dual therapy remains very poor. Preliminary studies of amantadine suggest that this drug could be potentially effective to treat hepatitis C. Design : randomized, double-blind, multicenter trial. Interventions compared : Peg-interferon alfa 2A + ribavirin + amantadine versus Peg-interferon alfa 2A + ribavirin + Placebo Eligibility criteria : Chronic hepatitis C, previously treated with combination of interferon plus ribavirin for at least 24 weeks,detectable HCV RNA. primary outcome : sustained virological response, defined as an undetectable HCV RNA level 24 weeks after the end of anti HCV treatment.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Chronic hepatitis C Previously treated with a combination of interferon plus ribavirin for at least 24 weeks Detectable HCV RNA (i.e. non responders) Signed informed consent Evidence of another cause of liver disease Liver cirrhosis (childPugh stage BMC) Alcohol consumption &gt; 30g/day for women or &gt; 40g/day for men ; drug abuse Other serious relevant disorders : psychiatric condition (especially depression), cardiovascular disease, renal decompensation, seizure history, hemoglobinopathy, autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Hepatitis C, chronic</keyword>
	<keyword>HCV infection</keyword>
	<keyword>Treatment failure</keyword>
	<keyword>PEG Interferon</keyword>
	<keyword>(Interferons/therapeutic use</keyword>
	<keyword>Interferon Alfa-2a/adverse effects)</keyword>
	<keyword>ribavirin</keyword>
	<keyword>(Ribavirin/therapeutic use</keyword>
	<keyword>Ribavirin/adverse effects)</keyword>
	<keyword>Amantadine</keyword>
	<keyword>Drug Therapy, Combination</keyword>
</DOC>